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Abstract
Background: It has been hypothesized that the virulence of lab-passaged Mycobacterium tuberculosis and recombinant M.
tuberculosis mutants might be reduced due to multiple in vitro passages, and that virulence might be augmented by
passage of these strains through mice before quantitative virulence testing in the mouse or guinea pig aerosol models.
Methodology/Principal Findings: By testing three M. tuberculosis H37Rv samples, one deletion mutant, and one recent
clinical isolate for survival by the quantitative organ CFU counting method in mouse or guinea pig aerosol or intravenous
infection models, we could discern no increase in bacterial fitness as a result of passaging of M. tuberculosis strains in mice
prior to quantitative virulence testing in two animal models. Surface lipid expression as assessed by neutral red staining and
thin-layer chromatography for PDIM analysis also failed to identify virulence correlates.
Conclusions/Significance: These results indicate that animal passaging of M. tuberculosis strains prior to quantitative
virulence testing in mouse or guinea pig models does not enhance or restore potency to strains that may have lost
virulence due to in vitro passaging. It is critical to verify virulence of parental strains before genetic manipulations are
undertaken and comparisons are made.
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Introduction
Serial in vitro passaging of pathogenic bacteria and viruses is a
classical method for obtaining attenuated strains that can be used
either as vaccines or as safe laboratory model strains to study basic
functions of the pathogen [1]. Examples in tuberculosis include the
Bacille Calmette-Gue ´rin (BCG) vaccine strain and H37Ra
obtained by intentional serial culture of virulent Mycobacterium
bovis and the variably virulent M. tuberculosis H37 strain,
respectively [2,3].
The question of whether to maintain the virulence of tubercle
bacilli through animal passage may have its roots in the personal,
legal, and scientific disputes between Robert Koch and his student
Emil von Behring in the late 19
th and early 20
th century [4,5,6].
Koch reviewed the ‘‘law of increasing virulence,’’ originally
enunciated by Casimir Davaine in studies of anthrax, that an
initial animal passage could ‘‘select’’ bacteria that were more
pathogenic than those in the original tissue source [7]. Koch does
not appear to have pursued this line of enriching bacterial
virulence in his studies of tuberculosis. In fact, as an adherent of
the monomorphic school of bacteriology [8,9], he emphasized the
stability of the organism from host to culture to new host [10]. Von
Behring sought to define a therapy for tuberculosis after Koch’s
failure to cure patients with tuberculin. Anti-toxin therapy, for
which von Behring received the first Nobel Prize ever awarded in
Medicine in 1901, was rapidly recognized to have no likelihood of
success against TB as it had had against diphtheria. Seeking a
vaccine against cattle tuberculosis in order to prevent transmission
of bovine bacilli through the digestive tract, which he proposed to
nearly always occur in childhood and to be a prerequisite for adult
pulmonary disease [6], von Behring reported in his Nobel Lecture
[11] that tubercle bacilli derived from human sputum were not
‘‘unharmful’’ for cows but that they lost their virulence ‘‘through
long-continued culture [6.5 years [2]] in the laboratory.’’ These
bacilli could be restored to ‘‘considerable virulence in cattle’’ after
passage through goats on his Marburg farm [5,11]. Earlier that
same year Koch had proposed in London that there may be
differences in the bacteria that cause human and bovine
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primacy of the pulmonary route of infection from human to
human, continued to dismiss the significance of bovine TB for
humans, and only reluctantly yielded on this point at the close of
Sixth International Conference on Tuberculosis in 1908 in
Washington, DC. There, Theobald Smith successfully made the
case for the distinct nature of the bovine bacillus, insisted, with
Ravenel and Arloing, on its impact on child health, and initiated a
campaign for its eradication in cattle in North America [4,7].
While the research into practical preventive or therapeutic
treatments of tuberculosis of both Berhing (immune milk) and
Koch (tuberculin) was ultimately unsuccessful, Behring’s vaccine
work and concepts of attenuation of M. tuberculosis, based in part
on the work of Pasteur with anthrax and rabies, almost certainly
influenced that of Calmette and Gue ´rin – an influence that was
never acknowledged, apparently due to bitter experiences arising
from World War I [5].
A century later, specifically over the last 20 years, tools to
genetically manipulate M. tuberculosis have been widely used.
Quantitative virulence comparison of genetically manipulated
strains together with their parental wild type strains is a widely
used technique for the identification of specific genetic determi-
nants of virulence. However, the process of generating such
mutants often begins with parent strains that have been repeatedly
passaged in vitro and the process itself involves multiple cycles of in
vitro growth which may diminish virulence in a non-specific
manner by selecting variants that are best adapted to in vitro
conditions. In addition, the host strains used for the manipulation
may themselves have undergone prolonged in vitro culture.
Because of these concerns, some investigators routinely passage
recombinant strains through mice or other animals before
conducting a definitive quantitative virulence assay in an animal
model [13]. Pre-passaging recombinant mycobacteria through
mice or other animals is costly and time-consuming and may also
result in unwanted attenuating changes. Importantly, the necessity
of pre-passage of M. tuberculosis through an animal host has not
been scientifically validated. Therefore, we conducted a controlled
comparison of the virulence of identical strains passaged and non-
passaged in both the mouse and guinea pig tuberculosis models.
Our results show no evidence of enhanced virulence of wild-
type M. tuberculosis strains or a deletion mutant in mice or guinea
pigs after mouse passaging or reduced virulence in strains that
have not been passaged.
Materials and Methods
Mouse passaging
M. tuberculosis strains (0.2 ml) at early-to-mid log phase in
Middlebrook 7H9 broth supplemented with 10% oleic acid-
albumin-dextrose-catalase (OADC) (Difco) and 0.1% Tween 80
were injected into the lateral tail vein of Swiss mice, and lungs
were harvested approximately 10 days after infection. Lung
homogenates were serially diluted and plated on Middlebrook
7H10 or 7H11 agar supplemented with 10% OADC. After 2–3
weeks, 5–10 colonies were collected and sub-cultured in 7H9
broth for 5–7 days and intravenous infection was repeated. After
this second mouse passage the isolate was grown in 7H9 broth to
an od600 of 1.0, divided into 1 ml aliquots and frozen at 270uC
with the addition of 10% glycerol.
Animal infections
Three M. tuberculosis H37Rv samples, one deletion mutant, and
one recent clinical isolate were tested in mouse intravenous or
mouse or guinea pig aerosol infection models. One H37Rv strain
(termed JHU, obtained from the Johns Hopkins Hospital clinical
microbiology laboratory [14]) had been passaged multiple times
through mouse lungs after intravenous infection. A second H37Rv
strain (TAMU) obtained from ATCC (#27294; preparation
described in [15]) was cultured once in Middlebrook 7H9
(M7H9) and frozen for up to 2–3 years before use. A viable
count (typically, 2610
7 cfu/ml) of the frozen/thawed and briefly
sonicated suspension was used to calculate the dilution for the
desired infectious dose in physiological saline to be put in the
Collison 3-jet nebulizer (#MRECN24) and exposure of guinea
pigs in a Madison chamber [16]. The third H37Rv strain (the
parent for a dosR deletion mutant) was obtained from D. Sherman
(Seattle, WA) and passaged twice through mouse lungs. We also
had the dosR deletion mutant in the pre-passage and twice-
passaged state. A final strain tested was SA294 (from Drs. Theus
and Eisenach), a recent clinical isolate with 15 IS6110 bands
detected by restriction fragment length polymorphism analysis and
found in a single case that was unpassaged and twice-passaged in
mice. Female mice (6 weeks old either BALB/c, our standard
strain or, on request, C57BL/6, Charles River Laboratories,
Wilmington, MA) were exposed to aerosol containing M.
tuberculosis in a Middlebrook inhalation exposure system (Glas-
Col, Terre Haute, IN) that resulted in ,2–3 log10 M. tuberculosis
implanted on day 1. All protocols were approved by the
Institutional Animal Care and Use Committees at Johns Hopkins
University (# MO04M380 and MO05M168) or at Texas A&M
University (#2006-96).
CFU and histopathology analysis
Mouse lungs were obtained after sacrifice and homogenized.
Serial dilutions of the homogenate were plated on selective
Middlebrook 7H11 plates (Becton-Dickinson, Sparks, MD)
containing antibiotics to prevent the growth of contaminating
organisms. Similarly, the lower right lobe of guinea pig lungs was
used for cfu determinations on Middlebrook 7H10 plates. The
lower left lobe was placed in 10% formalin and shipped to JHU for
histopathological analysis of hematoxylin and eosin-stained
sections.
Lung pathology
The number of low power (206) fields was counted for each
specimen. Within each field, the number of granulomas was also
tabulated permitting the calculation of the number of granulomas
per low-power microscopic field. Because the size and extent of
necrosis of each granuloma varies, a subjective determination on a
scale of 1–4 of disease severity was also assessed so that both
quantitative and qualitative measures could be used to describe the
extent of tissue damage in a manner similar to the method used in
a recent publication [17]. The identity of the specimen was
shielded from the scorer.
Surface Lipid Profile analysis
Neutral red assays were carried out as described previously
[18,19]. Briefly, colonies from selected strains were collected and
placed in an Eppendorf tube containing 1 ml of 50% methanol,
washed twice and kept for 1 hr at 37uC before incubation with
0.002% neutral red in barbital buffer. Color of test strains and
H37Rv (red) and H37Ra (yellow) controls were compared after
incubation and again after standing at room temperature
overnight. Assessment of phthiocerol dimycoserosate (PDIM) was
carried out using minor adaptations from previous studies
(e.g.,[18]). Briefly, strains were grown in broth to an od600 of 1.5
and the cell pellet was inactivated by autoclaving. Lipids were
extracted with 2:1 chloroform/methanol. A portion of the lower
M. tuberculosis Virulence
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(TLC) plate and run in a hexane:diethylether: acetic acid solvent
system. The TLC plate was treated with 10% phosphomolybdate
in ethanol, heated, and the plate was scanned.
Results
Unpassaged and twice-passaged clinical isolate shows
similar multiplication in BALB/c mouse lungs
In order to evaluate the effect of mouse passaging as described
in the Methods section on a recent slow-growing clinical isolate,
SA294, we compared the multiplication in lungs of the unpassaged
isolate to the mouse passaged strain using 3 BALB/c mice/group
in the mouse intravenous infection model. As may be seen in
Figure 1A, implantation was similar as assessed on day 1 and both
strains multiplied at similar rates until day 28 with cfu levels
determined at weekly intervals. We then compared the passaged
SA294 strain with the JHU H37Rv strain that has been regularly
passaged in mice in the mouse aerosol model with 6 BALB/c
mice/group. Although the implantation dose was lower for the
recent clinical isolate, the rates of growth in the two strains were
parallel (Fig. 1B). These data suggest that this recent clinical isolate
was not attenuated in its ability to multiply in mice and that
intravenous passage of the strain through mice did not result in an
enhanced ability to multiply in BALB/c mouse lungs.
Unpassaged and twice-passaged H37Rv parent strain
and dosR deletion mutant show similar multiplication in
C57BL/6 mouse lungs
Using the mouse aerosol model with 5 C57BL/6 mice/group,
we compared multiplication of an H37Rv strain and a dosR
deletion mutant constructed from it, using isolates that had or had
not been mouse passaged. C57BL/6 mice were used to test the
hypothesis that DdosR was hypervirulent and this should be
evaluated in a relatively resistant mouse strain [20]. All strains had
similar day 1 implantation. The parental strain multiplied
considerably better than did the mutant strain, as assessed by
lung CFU counts at days 14, 28, and 56, but there were no
differences between the passaged and unpassaged strains (Fig. 2).
Dissemination to the spleen was also not enhanced in the mouse-
passaged strains (data not shown). These data indicate that mouse
passaging had no impact on the ability of the wild-type or mutant
strain to implant and multiply in mouse lungs or to spread to an
extrapulmonary site.
Guinea pig lung pathology with type strains of H37Rv
from different institutions
Many institutions have a type strain of M. tuberculosis obtained in
the remote past, which is used as the standard reference in animal
virulence testing in their laboratories. To quantify the virulence of
two H37Rv strains used extensively over long periods of time at
two such institutions, we conducted comparative testing of the
JHU and TAMU H37Rv strains in the guinea pig aerosol model.
The JHU H37Rv strain was twice mouse passaged before being
divided into aliquots and frozen prior to use, while the TAMU
strain after receipt from the ATCC was grown once in large
quantity in vitro, aliquoted, and then frozen prior to use.
Quantitative organ CFU analysis showed nearly comparable
growth in guinea pig lungs (Fig. 3A). By two-way ANOVA
analysis, there were no statistically significant differences between
the JHU and TAMU strains at day 1 or week 3 while at week 6 the
difference in the lungs was of borderline statistical significance
(p=0.044). Spleen CFU counts of TAMU and JHU strains
(Fig. 3B) were not different at week 3 but were higher for the
TAMU strain at week 6 (p,0.01).
In addition, we conducted a lung pathology assessment using
the scoring system described in the Methods section. Lung
pathology was somewhat more severe in guinea pigs infected with
the unpassaged TAMU strain (Table 1) based on the number of
granulomas per field or the subjective quantitative scoring system.
Although both the TAMU and JHU strains induced large
numbers of granulomas, the lung granulomas were larger and
more often coalesced in TAMU strain-infected guinea pigs and
thereby occupied a greater area per low-power microscopic field
(Fig. 4). Overall, in the guinea pig aerosol model, the TAMU
H37Rv strain, obtained from the ATCC, propagated in
Middlebrook broth and frozen, was either comparable or more
Figure 1. A. Multiplication of mouse-passaged and -unpas-
saged M. tuberculosis clinical isolate in BALB/c mice. A. Growth in
lungs of the isolate following intravenous infection. B. Growth in lungs
following aerosol infection of mouse-passaged clinical isolate in
comparison with regularly mouse-passaged H37Rv strain (JHU) in
BALB/c mice. Errors are SD.
doi:10.1371/journal.pone.0010289.g001
M. tuberculosis Virulence
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terms of lung CFU counts, spleen CFU counts, or lung pathology.
Lipid profile analysis
All strains were positive for neutral red and all strains expressed
PDIMs (data not shown). Lipid phenotyping was therefore not
informative in these experiments.
Discussion
Serial in vitro culture has been used since the time of Pasteur
(reviewed in Smith, 1988) to attenuate microbial pathogens for use
as vaccines or defined laboratory strains. The H37 clinical isolate
was obtained from a 19-year old male patient at the Trudeau
sanatorium in New York, in 1905. Steenken and Gardner [3]
described the media used at Trudeau during the time, until 1922,
in which the isolate maintained its virulence for rabbits and guinea
pigs. The critical component appeared to be a peptone imported
from Germany. By the time the supply was exhausted, the
company was no longer in business and substitution with a
domestic peptone resulted in a marked, abrupt, but variable, loss
of virulence in the strain. Eventually, avirulent H37Ra and
virulent H37Rv were dissociated, using different culture media,
from this semi-virulent M. tuberculosis H37 in 1934 [3,21].
However, even at the time that H37Rv was made the type strain
at the ATCC, Kubica et al. [15] noted that many cultures of
H37Rv were no longer virulent for common laboratory animal
hosts and recommended a form of the Proskauer-Beck medium
most suitable for virulence maintenance, underlining the impor-
tance of a slightly alkaline pH of 7.4.
In his Nobel Lecture, Emil von Behring noted that tubercle
bacilli directly obtained from humans were not ‘‘unharmful’’ for
cattle, that they lost virulence during long-continued culture, but
could be restored to full cattle virulence by passage through goats
[11]. Calmette, the co-discover of attenuated M. bovis, or BCG,
wrote in 1920 that virulence testing required the use of strains
directly derived from infected organs or after a single culture after
passage in guinea pigs [2]. Investigations on variability of virulence
of tubercle bacilli were published in the 1950s [22,23,24]. Notably,
Steenken reported, in a review [25], that animal passaging had
never resulted in reversion of an avirulent strain. However, there
were some cases in which attenuated bacilli, probably containing a
virulent subpopulation, may have preferentially propagated after
animal passaging or after culture in synthetic media. Guinea pig
testing in the 1950s suggested that strains maintained in vitro were
less virulent for guinea pigs (J. Grosset, personal communication).
Isoniazid-resistant M. tuberculosis, was also reported to be less
virulent for guinea pigs [26]. In 1988, Grosset and Ji [13]
recommended that a well-characterized, drug-susceptible strain
‘‘whose virulence is maintained through regular passages in the
mouse, is the strain of choice.’’ Reports from other contemporary
tuberculosis investigators vary in the particulars of the best
procedure to use but also support this principle of virulence
maintenance through mouse passaging [27,28]. We have been
unable to find studies directly comparing passaged and unpassaged
strains. Recently, Ahmad et al. reported results consistent with
Figure 2. Comparison of bacterial multiplication in the lungs of
C57BL/6 mice by passaged and unpassaged dosR deletion
mutants and their parental M. tuberculosis H37Rv strain
following aerosol infection. Errors are SD.
doi:10.1371/journal.pone.0010289.g002
Figure 3. Mouse passaged JHU M. tuberculosis H37Rv strain
compared to in vitro propagated TAMU H37Rv strain in guinea
pigs after aerosol infection. Errors are SEM.
doi:10.1371/journal.pone.0010289.g003
M. tuberculosis Virulence
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strains of H37Rv in guinea pigs [29].
Mouse passaging has been proposed as a technique to eliminate
less fit phenotypic variant subpopulations that may emerge during
prolonged in vitro cultivation [30]. It has been thought that the
less virulent variants would fail to survive due to immunological
mechanisms present in the mouse. These would necessarily be
components of innate immunity due to the short time (,2 weeks)
from infection to the harvest of lung tissue. Alternatively, there
may be a deficiency in the ability of the less virulent
subpopulations to obtain nutrients after injection into the host as
proposed by Pierce et al [24]. Others have hypothesized that
survival of bacteria to the chronic phase in a resistant mouse strain
should select for more virulent strains [31]. Finally, it is possible
that under the conditions used, in vitro passaging at least for
modest periods does not select for less virulent variants that
multiply less vigorously or fail to survive after animal infection.
We hypothesized that defined M. tuberculosis mutants and their
H37Rv parent strains, would have reduced virulence and could be
restored to full virulence by passage through mice before testing in
the mouse or guinea pig aerosol models. We expected that mouse
passaging would eliminate the less fit (i.e., less virulent) sub-
populations. As described above, however, the passaging proce-
dures used on the strains compared to date had no impact on the
virulence phenotype observed in mice or guinea pigs. In fact, as
would have been predicted by the late Frank Collins [21],
someone had already ‘‘been there, done that.’’ Arnold Rich [32]
cited nearly parallel passaging experiments done at the Trudeau
Institute [33] and at Johns Hopkins [34] in guinea pigs over a 10-
year period in the 1920s with the R1 strain that was known to have
reduced virulence, but not to be avirulent. Essentially none of the
isolates after each passage was markedly different from the
parental strain in its ability to cause progressive disease. On the
other hand, a fully virulent isolate rapidly lost virulence through
serial in vitro culture. If the latter isolate was passaged in guinea
pigs, from the beginning, it retained full virulence.
One limitation of our study is that our endpoints were limited to
organ CFU survival and in some cases tissue pathology. We did
not compare the passaged and unpassaged strains for differences in
time-to-death. Time-to-death differences between genetically
defined strains of M. tuberculosis mutants have been reported in
the setting of indistinguishable organ CFU burdens [35,36]. In
addition, we tested only a limited number of passaged and non-
passaged strain pairs and our results may not be generalizable to
all strains maintained in vitro, particularly for extended periods,
prior to use in animals. Finally, for the experiments described, we
passaged strains by infecting mice intravenously whereas most of
the virulence assays were performed in aerosol infection models.
We cannot exclude the possibility that the in vivo passaging would
have a greater impact on virulence if the strain is passaged by the
same route of infection used in the virulence assay. Similarly, we
cannot exclude the possibility that the reduced multiplication of
the JHU H37Rv strain relative to the TAMU H37Rv strain in the
guinea pig was caused by repeated mouse passaging and selection
of characteristics favoring growth in mice that are detrimental to
growth in a different microenvironment present in the infected
guinea pig lung.
Although there is evidence documented in the literature that
loss of neutral red staining is associated with loss of virulence
[18,19,37] and that loss of PDIM expression is also associated with
loss of virulence [30,38,39,40,41,42], none of the strains used in
this study showed altered lipid expression. Although artificial
attenuation may occur with loss of PDIMs due to alteration in one
or more of the pps or drr genes or other regulatory elements [30],
our experience has also shown in other experiments that PDIM-
negative strains can retain full virulence in animals. Our practice is
to evaluate lipid profiles and, if negativity is found in the mutant
Figure 4. Comparison of inflammatory granulomatous pathol-
ogy in the lungs of guinea pigs three weeks after aerosol
infection with one of two H37Rv strains (unpassaged TAMU,
top, and mouse-passaged JHU, bottom).
doi:10.1371/journal.pone.0010289.g004
Table 1. Comparative lung histopathology in guinea pigs
infected with M. tuberculosis H37Rv with different histories of
in vitro and in vivo passaging.
H37Rv
Strain Week
Mean #
granulomas
granulomas/
field
Mean Score
(1–4)
TAMU* 3 30 .13 3.25
JHU** 3 26.5 10.6 2.5
TAMU* 6 16 6.4 3.5
JHU** 6 19.5 7.8 2.4
* Not passaged in mice.
** Passaged in mice.
doi:10.1371/journal.pone.0010289.t001
M. tuberculosis Virulence
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because of loss of the gene of interest and/or the loss of PDIMs.
Based on our findings, we advocate the generation of mutants in
parental strains known to be virulent and then to proceed to direct
testing of M. tuberculosis strains in animal models, without insisting
on a prerequisite for animal passaging. Our data support the
practice of banking seed lots of reference strains at 280uC and
using them for in vivo virulence testing directly instead of requiring
one or two rounds of animal passage prior to virulence testing.
Once a strain has lost virulence, restoration through animal
passaging appears unlikely to succeed.
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